Protalix BioTherapeutics, Inc. (PLX): Capital Expenditures
$1.64M
Year ended 2025-12-31
$2.25M
Trailing 12 months to 2026-06-30
+37.7%
3-year compound annual growth
+20.1%
5-year compound annual growth
+13.4%
10-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $1.64M | +27.8% | 2026-03-18, From 2025-01-01 |
| 2024-12-31 | $1.28M | +11.6% | 2026-03-18, From 2024-01-01 |
| 2023-12-31 | $1.15M | +83.0% | 2026-03-18, From 2023-01-01 |
| 2022-12-31 | $628.0K | -57.0% | 2025-03-17, From 2022-01-01 |
| 2021-12-31 | $1.46M | +122.7% | 2024-03-14, From 2021-01-01 |
| 2020-12-31 | $655.0K | +4.5% | 2023-02-27, From 2020-01-01 |
| 2019-12-31 | $627.0K | -8.6% | 2022-03-31, From 2019-01-01 |
| 2018-12-31 | $686.0K | -29.4% | 2021-03-30, From 2018-01-01 |
| 2017-12-31 | $971.0K | +14.4% | 2020-03-12, From 2017-01-01 |
| 2016-12-31 | $849.0K | +83.0% | 2019-03-18, From 2016-01-01 |
| 2015-12-31 | $464.0K | -40.9% | 2018-03-06, From 2015-01-01 |
| 2014-12-31 | $785.0K | -58.5% | 2017-03-16, From 2014-01-01 |
| 2013-12-31 | $1.89M | -8.6% | 2016-03-08, From 2013-01-01 |
| 2012-12-31 | $2.07M | -63.8% | 2015-03-12, From 2012-01-01 |
| 2011-12-31 | $5.71M | -27.4% | 2014-03-13, From 2011-01-01 |
| 2010-12-31 | $7.86M | +26.8% | 2013-02-28, From 2010-01-01 |
| 2009-12-31 | $6.20M | n/a | 2012-02-27, From 2009-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Protalix BioTherapeutics, Inc. (PLX) | 2025-12-31 | $1.64M | +27.8% |
| Invivyd, Inc. (IVVD) | 2025-12-31 | $155.0K | +10.7% |
| Champions Oncology, Inc. (CSBR) | 2026-04-30 | $564.0K | +45.0% |
| Vir Biotechnology, Inc. (VIR) | 2025-12-31 | $4.83M | -33.8% |
| Editas Medicine, Inc. (EDIT) | 2025-12-31 | $607.0K | -93.1% |
| Voyager Therapeutics, Inc. (VYGR) | 2025-12-31 | $2.60M | -26.3% |
| Black Diamond Therapeutics, Inc. (BDTX) | 2024-12-31 | $0 | -100.0% |
| Sangamo Therapeutics, Inc (SGMOQ) | 2025-12-31 | $102.0K | -61.8% |
| Kymera Therapeutics, Inc. (KYMR) | 2025-12-31 | $1.45M | -88.7% |
Compare PLX, IVVD, CSBR, VIR side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗